Association of Low Serum 25OHD Levels with Abnormal Bone Microarchitecture in Well-Differentiated Thyroid Cancer.

The association of low levels of 25 hydroxyvitamin D (25OHD) with papillary thyroid cancer (PTC) is being studied, as to whether it is a risk factor or as a coincidental one. This study aimed to evaluate serum levels of deficiency, insufficiency, and sufficiency of 25OHD in PTC and its relationship with the trabecular bone score (TBS) and bone mineral density (BMD). This study includes 134 postmenopausal women with PTC, followed for 10 years. BMD was measured with DXA Hologic QDR 4500, and TBS with Med-Imaps iNsight2.0 Software. Mean serum 25OHD was 23.09 ± 7.9 ng/mL and deficiency, insufficiency, and sufficiency levels were 15.64 ± 2.9, 25.27 ± 2.7, and 34.7 ng/mL, respectively. Parathyroid hormone (PTH) and bone alkaline phosphatase (BAP) were higher in deficiency (57.65 ± 22.6 ng/mL; 29.5 ± 14 U/L) and in insufficiency (45.88 ± 19.8 ng/mL; 23.47 ± 8.8 U/L) compared with sufficiency of 25OHD (47.13 ± 16 and 22.14± 9.7 ng/mL) (p = 0.062 and p = 0.0440, respectively). TBS was lower in patients with 25OHD < 20 ng/mL (1.24 ± 0.13) compared with between 20-29 (1.27 ± 0.13, p < 0.05) and 30 ng/mL (1.31 ± 0.11, p < 0.01). We found low TBS in patients with PTC and long-term follow-up associated with low serum 25OHD levels, not associated with cancer stage, or accumulative iodine radioactive dose. Low 25OHD associated with deleterious bone quality in patients with PTC should be restored for the prevention of fractures.

Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.

BACKGROUND: Conflicting results has been reported regard osteoporosis and fractures in patients with Differentiated Thyroid Cancer (DTC). Our objective was to evaluate the long-term effects of TSH suppression therapy with Levothyroxine (LT4) on trabecular bone score (TBS) and bone mineral density (BMD) in females with DTC after thyroidectomy. METHODS: About 145 women with resected DTC and receiving long-term TSH therapy, were stratified according to the degree of TSH suppression. Mean duration of follow-up was 12.3 ± 6.1 years. BMD and TBS, were assessed using dual-energy X-ray absorptiometry (DXA) and TBS iNsight (Med-Imaps), at baseline (1-3 months after surgery) and at the final study visit. RESULTS: In patients stratified by duration of TSH suppression therapy (Group I, 5-10 years; Group II, >10 years), slight increases from baseline TSH levels were observed. Significant decreases in LS-BMD and FN-BMD were seen in patients after >10 years. TBS values were lower in Groups I (1.289 ± 0.122) and II (1.259 ± 0.129) compared with baseline values (P = .0001, both groups). Regarding the degree of TSH suppression, TBS was significantly reduced in those with TSH < 0.1 µU/mL (P = .0086), and not in patients with TSH suppression of 0.1.-0.5 or >0.5 µU/mL. CONCLUSIONS: We found deterioration of trabecular structure in patients with DTC and TSH suppression therapy below 0.1 µU/mL and after 5-10 years of follow-up. Significant changes in BMD according to TSH levels were not observed. Trabecular Bone Score is a useful technique for identifying thyroid cancer patients with risk of bone deterioration.

[Prospective study of digestive stomas complications]. / Estudio prospectivo sobre las complicaciones de los estomas digestivos.

The surgical treatment of colorectal pathology can often lead to the need for a stoma, either colostomy or ileostomy. This surgery is associated with a high rate of complications. OBJECTIVE: The objective of this study is to describe the frequency of stomas complications, identify associated risk factors as well as new prevention strategies. MATERIALS AND METHODS: Prospective observational cohort study on patients who underwent an ileostomy or colostomy at the Hospital U. Infanta Leonor between April 2016 and October 2017. RESULTS: A total of 87 stomas were performed in 83 patients, of which 77.01% had at least one complication. The most presented complication was dermatitis (54.02%), followed by detachment (40.23%) and flat stoma (21.84%). The greatest number of complications occurred in the second week of the postoperative period. The average height of the stomas made was 10.6 mm. BMI was associated as a risk factor for the development of stoma complications. Of all the patients, 55 had follow-up until 6 months. CONCLUSION: Although our complication rate is high, this outcome is similar to others studies previously published. BMI was the unique risk factor associated with the development of stoma complications. New strategies related to the surgical technique can be developed to decrease our complication rate.

Estudio prospectivo sobre las complicaciones de los estomas digestivos

El tratamiento quirúrgico de la patología colorrectal puede conllevar en muchas ocasiones la necesidad de realizar un estoma, ya sea colostomía o ileostomía. Este tipo de cirugía se asocia a una alta tasa de complicaciones. Objetivo: El objetivo de este estudio es describir la frecuencia de las complicaciones, identificar factores de riesgo así como estrategias de prevención. Materiales y métodos: Estudio de cohorte observacional prospectiva, de pacientes a los que se les realizó ileostomía o colostomía en el Hospital Universitario Infanta Leonor entre abril de 2016 y octubre de 2017. Resultados: Se realizaron un total de 87 estomas en 83 pacientes, de los cuales un 77,01% presentó al menos una complicación. La complicación más presentada fue la dermatitis (54,02%), seguida del desprendimiento (40,23%) y del estoma plano (21,84%). El mayor número de complicaciones se dieron en la segunda semana del postoperatorio. La altura media de los estomas realizados fue 10,6 mm. Se ha encontrado el índice de masa corporal como factor de riesgo asociado al desarrollo de complicaciones de las ostomías, no existiendo significación estadística en nuestros pacientes con respecto al resto de factores estudiados. Conclusiones: Nuestra tasa de complicaciones es similar a lo publicado previamente en la literatura. El índice de masa corporal ha sido el único factor de riesgo de nuestra serie. Se han encontrado puntos susceptibles de mejora con respecto a la técnica quirúrgica para reducir el número de complicaciones.

The surgical treatment of colorectal pathology can often lead to the need for a stoma, either colostomy or ileostomy. This surgery is associated with a high rate of complications. Objective: The objective of this study is to describe the frequency of stomas complications, identify associated risk factors as well as new prevention strategies. Materials and methods: Prospective observational cohort study on patients who underwent an ileostomy or colostomy at the Hospital U. Infanta Leonor between April 2016 and October 2017. Results: A total of 87 stomas were performed in 83 patients, of which 77.01% had at least one complication. The most presented complication was dermatitis (54.02%), followed by detachment (40.23%) and flat stoma (21.84%). The greatest number of complications occurred in the second week of the postoperative period. The average height of the stomas made was 10.6 mm. BMI was associated as a risk factor for the development of stoma complications. Of all the patients, 55 had follow-up until 6 months. Conclusion: Although our complication rate is high, this outcome is similar to others studies previously published. BMI was the unique risk factor associated with the development of stoma complications. New strategies related to the surgical technique can be developed to decrease our complication rate.

rhIGF-1 Treatment Increases Bone Mineral Density and Trabecular Bone Structure in Children with PAPP-A2 Deficiency.

AIM: Our objective was to determine changes in bone mineral density (BMD), trabecular bone score (TBS), and body composition after 2 years of therapy with recombinant human insulin-like growth factor-1 (rhIGF-1) in 2 prepubertal children with a complete lack of circulating PAPP-A2 due to a homozygous mutation in PAPP-A2 (p.D643fs25*) resulting in a premature stop codon. METHODS: Body composition, BMD, and bone structure were determined by dual-energy X-ray absorptiometry at baseline and after 1 and 2 years of rhIGF-1 treatment. RESULTS: Height increased from 132 to 145.5 cm (patient 1) and from 111.5 to 124.5 cm (patient 2). Bone mineral content increased from 933.40 to 1,057.97 and 1,152.77 g in patient 1, and from 696.12 to 773.26 and 911.51 g in patient 2, after 1 and 2 years, respectively. Whole-body BMD also increased after 2 years of rhIGF-1 from baseline 0.788 to 0.869 g/cm2 in patient 1 and from 0.763 to 0.829 g/cm2 in patient 2. After 2 years of treatment, both children had an improvement in TBS. During therapy, a slight increase in body fat mass was seen, with a concomitant increase in lean mass. No adverse effects were reported. CONCLUSION: Two years of rhIGF-1 improved growth, with a tendency to improve bone mass and bone microstructure and to modulate body composition.

Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center.

BACKGROUND: Adult growth hormone deficiency (AGHD) is characterized by impaired physical activity, diminished quality of life (QoL), weight and fat mass gain, decreased muscle mass and decreased bone mineral density (BMD). The aim of this study was to evaluate the effects of long-term treatment (7 years) with recombinant human growth hormone (rhGH) on metabolic parameters, body composition (BC), BMD, bone microarchitecture and QoL. PATIENTS AND METHODS: In this prospective study, BMD and BC were assessed by dual-energy X-ray absorptiometry (DXA). Bone microarchitecture was assessed with the trabecular bone score (TBS). The QoL-AGHDA test was used to assess QoL. RESULTS: A total of 18 AGHD patients (mean age, 37.39 ± 12.42) were included. Body weight and body mass index (BMI) showed a significant increase after 7 years (p = 0.03 and p = 0.001, respectively). There was a significant tendency of body fat mass (BFM) (p = 0.028) and lean body mass (LBM) (p = 0.005) to increase during the 7 years of rhGH treatment. There was a significant increase in lumbar spine (LS) BMD (p = 0.01). TBS showed a nonsignificant decrease after 7 years of treatment, with a change of -0.86% ± 1.95. QoL showed a large and significant improvement (p = 0.02). CONCLUSION: Long-term rhGH treatment in AGHD patients induces a large and sustained improvement in QoL. Metabolic effects are variable with an increase in LBM as well as in BMI and BFM. There is a positive effect on BMD based on the increase in LS BMD, which stabilizes during long-term therapy and is not associated with a similar increase in bone microarchitecture.

Recalcitrant hypocalcaemia in a patient with post-thyroidectomy hypoparathyroidism and Roux-en-Y gastric bypass.

INTRODUCTION: Roux-en-Y gastric bypass (RYGB) places patients at an increased risk of hypocalcaemia due to the reduction in calcium absorption (because the procedure bypasses the duodenum and jejunum) and vitamin D deficiency. Subsequent thyroid surgery increases the risk of severe hypocalcaemia due to potential post-operative hypoparathyroidism. Only a few cases have been published before of this type of treatment-challenging hypocalcaemia. CLINICAL PRESENTATION: We report the case of a 31-year-old woman with a previous RYGB, who suffered severe and symptomatic chronic hypocalcaemia after total thyroidectomy. She required aggressive therapy with oral calcium and calcitriol and frequent calcium infusions, but there was no improvement in serum calcium level. Due to the lack of response to standard therapy, teriparatide treatment was started (first with subcutaneous injections and thereafter with a multipulse subcutaneous infusor) but the results were disappointing. As there was no response to different medical treatments, reversal of RYGB was performed with no complications and a subsequent sustained increase in serum calcium level. CONCLUSIONS: This case shows that patients with postoperative hypoparathyroidism and RYGB have increased risk of severe recalcitrant symptomatic hypocalcaemia. In our case teriparatide was ineffective but, as this is the first patient reported, more results are needed to evaluate properly the effect of teriparatide in this multifactorial hypocalcaemia. Reversal of RYGB should be considered when medical therapy has failed, because surgery restores an adequate absorption of calcium and vitamin D from previously bypassed duodenum and proximal jejunum.